Job title: Associate Director
Brian Long received his Ph.D. in Microbiology and Immunology from The University of North Carolina, Chapel Hill in 2004 and pursued post-doctoral training at The Gladstone Institutes and the University of California, San Francisco where he investigated the role of innate immunity in HIV disease pathogenesis. Following his post-doctoral training, he continued as a Research Scientist in the Division of Experimental Medicine at UCSF where he worked on the development and standardization of humanized mouse models for the evaluation of HIV immunology, therapeutics and drug discovery. Brian joined BioMarin in June of 2014 and is currently an Associate Director in Translational Sciences and Immunogenicity Assessment where he provides immunologic expertise to drug programs across developmental stages. Most recently, Brian has been responsible for developing the immunogenicity and safety strategies for novel biologic therapeutics including BMN 270, an AAV5 mediated gene therapy encoding human Factor VIII for the treatment of Hemophilia A. Brian has over 20 years of experience in immunology and infectious disease, autoimmunity, immunotherapy, cell signaling and drug development.
Live Q&A – Ask the speakers your questions 1:40 pm
day: Day Two
Translational and Clinical Immunogenicity of Valoctocogene Roxaparvovec, & AAV5-Mediated Gene Therapy for Hemophilia A 1:00 pm
• Bridging of non-clinical immunogenicity to clinical studies of Valoctocogene Roxaparvovec, an AAV5 mediated gene therapy encoding FVIII for the treatment of Hemophilia A • The development and characterization of assays used to detect pre-existing AAV5 immunogenicity will be discussed • Immunogenicity data characterizing the post-dosing humoral and cellular immune responses will be presentedRead more
day: Day Two